Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs.
Sturkenboom MGG, Märtson AG, Svensson EM, Sloan DJ, Dooley KE, van den Elsen SHJ, Denti P, Peloquin CA, Aarnoutse RE, Alffenaar JC. Sturkenboom MGG, et al. Among authors: van den elsen shj. Clin Pharmacokinet. 2021 Jun;60(6):685-710. doi: 10.1007/s40262-021-00997-0. Epub 2021 Mar 6. Clin Pharmacokinet. 2021. PMID: 33674941 Free PMC article. Review.
Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients.
van den Elsen SHJ, Sturkenboom MGG, Van't Boveneind-Vrubleuskaya N, Skrahina A, van der Werf TS, Heysell SK, Mpagama S, Migliori GB, Peloquin CA, Touw DJ, Alffenaar JC. van den Elsen SHJ, et al. Antimicrob Agents Chemother. 2018 Nov 26;62(12):e01092-18. doi: 10.1128/AAC.01092-18. Print 2018 Dec. Antimicrob Agents Chemother. 2018. PMID: 30373800 Free PMC article. Clinical Trial.
Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients.
van den Elsen SHJ, Sturkenboom MGG, Akkerman OW, Manika K, Kioumis IP, van der Werf TS, Johnson JL, Peloquin C, Touw DJ, Alffenaar JC. van den Elsen SHJ, et al. Antimicrob Agents Chemother. 2019 Jun 24;63(7):e00384-19. doi: 10.1128/AAC.00384-19. Print 2019 Jul. Antimicrob Agents Chemother. 2019. PMID: 31010868 Free PMC article.
Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs.
Kuhlin J, Sturkenboom MGG, Ghimire S, Margineanu I, van den Elsen SHJ, Simbar N, Akkerman OW, Jongedijk EM, Koster RA, Bruchfeld J, Touw DJ, Alffenaar JC. Kuhlin J, et al. Among authors: van den elsen shj. Clin Mass Spectrom. 2018 Oct 19;14 Pt A:34-45. doi: 10.1016/j.clinms.2018.10.002. eCollection 2019 Sep. Clin Mass Spectrom. 2018. PMID: 34934812 Free PMC article. Review.
Corrigendum to "Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs" [Clin. Mass Spectrom. 14(Part A) (2019) 34-45].
Kuhlin J, Sturkenboom MGG, Ghimire S, Margineanu I, van den Elsen SHJ, Simbar N, Akkerman OW, Jongedijk EM, Koster RA, Bruchfeld J, Touw DJ, Alffenaar JC. Kuhlin J, et al. Among authors: van den elsen shj. J Mass Spectrom Adv Clin Lab. 2022 Aug 13;25:72. doi: 10.1016/j.jmsacl.2022.08.001. eCollection 2022 Aug. J Mass Spectrom Adv Clin Lab. 2022. PMID: 36035622 Free PMC article.
Lack of penetration of amikacin into saliva of tuberculosis patients.
van den Elsen SHJ, Akkerman OW, Huisman JR, Touw DJ, van der Werf TS, Bolhuis MS, Alffenaar JC. van den Elsen SHJ, et al. Eur Respir J. 2018 Jan 11;51(1):1702024. doi: 10.1183/13993003.02024-2017. Print 2018 Jan. Eur Respir J. 2018. PMID: 29326320 Free article. No abstract available.
11 results